Ranibizumab mAb-based ELISA Assay


The Ranibizumab mAb-based ELISA Assay is for the specific determination of free Ranibizumab in aqueous humour. The Eagle Biosciences Ranibizumab (mAb-based) ELISA Assay Kit is for research use only and is not intended for diagnostic or therapeutic procedures.

Ranibizumab mAb-based ELISA Assay

The Ranibizumab mAb-based ELISA Assay is For Research Use Only

Size: 1 x 96 wells
Sensitivity: 0.33 ng/mL
Incubation Time: 2.5 hours
Sample Type:  Aqueous humour
Sample Size: 10 µL
Alternative Name: Lucentis

Assay Principle

This Ranibizumab mAb-based ELISA is based on a Ranibizumab-specific monoclonal antibody (catcher Ab, ImmunoGuide clone 2A1). Diluted standards and samples are incubated in the microtiter plate coated with IG-2A1 mAb. After incubation, the wells are washed. A biotinylated anti-human kappa light chain monoclonal antibody (clone ImmunoGuide 7G8(Z) is added and binds to the kappa light chain part of Ranibizumab. Following incubation, wells are washed, and the horseradish peroxidase (HRP)-conjugated streptavidin is added and binds to the biotinylated 7G8(Z) mAb. Following incubation, wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Ranibizumab in the sample or standard. Results of samples can be determined by using the standard curve. Preincubation of Ranibizumab with recombinant human VEGF inhibited the reaction. Therefore, the ImmunoGuide Ranibizumab ELISA (mAb-based) measures the free form of Ranibizumab.

Storage and stability of the Ranibizumab mAb-based ELISA Assay
The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the -corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.

Related Products to Ranibizumab mAb-based ELISA Assay

Ranibizumab (Lucentis) ELISA Assay Kit
Vedolizumab mAb-based ELISA
Infliximab ELISA mAb-based Assay

Additional Information

Assay Background

The drug Ranibizumab (trade name Lucentis®) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment (Fab) designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons.

The Eagle Biosciences Ranibizumab ELISA (mAb-based) kit can be efficiently used for measuring free Ranibizumab levels in aqueous humour.


There is no cross reaction with any other proteins present in native aqueous humour samples. A screening test was performed with different aqueous humour samples. All produced OD450/620 nm values (ranged from 0.016 to 0.023) less than the mean OD (0.134) of standard D (1 ng/mL). In addition, binding of Ranibizumab to the solid phase is inhibited by recombinant human VEGF. Therefore, the ImmunoGuide Ranibizumab ELISA (mAb-Based) measures the biologically active free form of Ranibizumab, i.e. not pre-occupied by human VEGF antigen. No cross reaction was observed with the other therapeutic antibodies including Infliximab, Rituximab, Veolizumab, Trastuzumab, Nivolumab and Aflibercept at concentrations tested up to 50 μg/mL. All produced mean OD450/620 nm values (ranged from 0.052 to 0.068) less than standard D. Because the 2A1 mAb, used for coating solid phase, is also reactive against Bevacizumab, it causes full cross reaction. But a quantification of Bevacizumab in aqueous homour by this testkit is possible only by using the drug-specific standards (i.e. Bevacizumab).

Package Inserts


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations